RetiNova Therapeutics

RetiNova Therapeutics is pioneering a novel class of regenerative biologics aimed at restoring vision in patients with retinal ischemic diseases. Its lead asset, Noregen™, is a first-in-class, complete norrin mimic that activates developmental pathways to regenerate functional retinal vasculature and neurons, going beyond the symptomatic control of current anti-VEGF standards. The company is targeting the large, underserved markets of DME and RVO, where millions of patients experience progressive vision loss despite frequent injections. RetiNova is a private, preclinical-stage biotech positioned to potentially revolutionize treatment outcomes through disease modification.

Synthetic protein engineering platform focused on creating complete mimics of the norrin protein, an atypical Wnt pathway ligand, to activate regenerative pathways for the blood-retina barrier and retinal neurons.

Competes directly with the dominant anti-VEGF franchise (Eylea, Lucentis, Vabysmo) and other emerging agents targeting angiogenesis, inflammation, or durability. Its regenerative approach is novel but may face competition from other neuroprotective or gene therapy strategies in development for retinal diseases.